MedTrace Logo

High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment

NCT03557437 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2019-06-18

No results posted yet for this study

Summary

Amoxicillin and metronidazole （400mg Q.D.S） based quadruple therapy had achieved a high cure rate in the rescue treatment of helicobacter pylori infection. This study aims to evaluate the efficacy and safety of the amoxicillin and metronidazole (400mg thrice a day) based triple therapy and the addition of bismuth in the naive patients with helicobacter pylori infection.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Esomeprazole

Proton pump inhibitor

DRUG

Amoxicillin, Metronidazole

Antibiotics for H. pylori eradication

DRUG

Bismuth Potassium Citrate

Gastric mucosal protective drug with anti-H. pylori effect

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Hong Lu, M.D · Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-25
Primary Completion
2019-06-10
Completion
2019-06-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03557437 on ClinicalTrials.gov